

Immuno-Oncology Market is Predicted to Reach US\$ 111.64 Billion by 2034, Expanding at a CAGR of 16.5% | Fact.MR

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact.MR Report

ROCKVILLE, MD, UNITED STATES, March 13, 2025 /EINPresswire.com/ -- The global [immuno-oncology market](#) is estimated to have a value of US\$ 24.17 billion in 2024. The market is projected to grow at a robust clip through 2034, with a CAGR of 16.5%. The demand for immuno-oncology is projected to hit a valuation of US\$ 111.64 billion by 2034.



As with other oncology-related fields, the growing incidence of cancer is seeing the demand for immuno-oncology accelerate. Significant growth in cigarette smokers, genetic diseases, excess sun exposure, and changing eating habits are leading factors in cancer growth, which further necessitates the use of immuno-oncology. The effectiveness of the treatment is a further boost for the market.

Immuno-oncology is a dynamic field, and newer modes of treatment and drugs keep the product line fresh. Significant sums of money and time are devoted to research and development for the introduction of new drugs. As governments all over the world look to curb death rates due to cancer, there is encouragement for the development of novel products from public health institutions.

As part of a more positive outlook towards immuno-oncology, regulatory bodies are approving newer products at a frequent pace. As companies in the market rely on approval from regulatory bodies like the United States Food and Drug Administration (FDA) to get their products moving, this positive tendency is a boon for the market.

For More Insights into the Market, Request a Sample of this Report:

Key Takeaways from the Market Study

The global immuno-oncology market is projected to expand at a CAGR of 16.5% through 2034. The East Asia immuno-oncology market is expected to evolve at a CAGR of 15.2% through the forecast period.

The immuno-oncology industry is expected to register a CAGR of 15.2% in China over the forecast period.

The immuno-oncology industry in Japan is expected to rise at a CAGR of 15.5% through 2034. Based on therapy type, immune checkpoint inhibitors lead the market, with an expected market share of 86.3% in 2024.

“Doctors often use immuno-oncology in combination with other cancer treatments. Immuno-oncology’s boosting of the immune system is paired up with other effective treatments to battle cancer cells. Thus, the market is growing in conjunction with other oncological markets.” says a Fact.MR analyst.

Leading Players Driving Innovation in the Immuno-Oncology Market

Key companies in the market are Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., Merck & Co., Inc., GSK Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc., Genentech Inc., Sanofi, and AstraZeneca.

Companies are Pairing Together to Combine Technological Capabilities in the Pursuit of More Effective Products

The market is fertile ground for the inking of partnerships, sometimes even between direct competitors. Startups and established giants alike are taking the opportunities provided by collaboration. Some prominent companies in the market are Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., and Merck & Co.

Some recent developments in the market are:

In December 2023, Elpiscience Biopharma joined forces with Astellas Pharma for research programs on cancer treatment.

In September 2023, GI Innovation partnered up with Medidata Solutions for the development of two new drugs- GI-101 and GI 102.

Get Customization on this Report for Specific Research Solutions-

https://www.factmr.com/connectus/sample?flag=S&rep_id=9418

Immuno-Oncology Industry News:

Elpiscience Biopharma and Astellas Pharma inked a contract in December 2023. Together, the businesses will conduct cancer treatment research projects, with Elpiscience eligible to receive financial incentives totalling more than US\$1.7 billion should milestones be reached.

American clinical trial data solution company Medidata Solutions signed an agreement with South Korean player GI Innovation in September 2023. In order to develop two new medications, GI-101 and GI-102, the South Korean company intends to take advantage of the American's AI and big data skills.

The agreement between Japanese company Takeda and American startup KSQ Therapeutics was extended in May 2023. With further financial incentives if their shared goals are reached, KSQ Therapeutics raised its investment in the Japanese player.

Segmentation of Immuno-oncology Market Research

By Therapy Type:

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Oncolytic Virus

Others

By Therapeutic Area:

Melanoma

Lung Cancer

Blood Cancers

Renal Cell Carcinoma

Prostate Cancer

Bladder Cancer

Other Cancers

By End User:

Hospitals

Clinics

Ambulatory Surgical Centers

By Region:

North America

Europe

Latin America

East Asia

South Asia & Oceania

The Middle East & Africa

Check out More Related Studies Published by Fact.MR:

The global [cancer immunotherapy market](#) is expected to reach US\$ 159.2 billion in 2024 and

grow at a 10% CAGR, hitting US\$ 412.8 billion by 2034 (Fact.MR).

The global [immune checkpoint inhibitor market](#) is set to reach US\$ 26.8 billion in 2024, with a 14.7% CAGR through 2034, hitting US\$ 106.2 billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Sales Team: sales@factmr.com

Follow Us: [LinkedIn](#) | [Twitter](#) | [Blog](#)

S. N. Jha

Fact.MR

+1 628-251-1583

sales@factmr.com

This press release can be viewed online at: <https://www.einpresswire.com/article/793393083>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.